Thyrocare Invests USD 4,75,000 in Tanzania JV

Thyrocare Technologies Limited has announced an additional investment of USD 4,75,000 (approximately ₹4.32 crore) in its subsidiary, Thyrocare Laboratories (Tanzania) Limited, on February 24, 2026. 

The investment has been made through the subscription of Compulsorily Convertible Irredeemable Preference Shares (CCPS).

Thyrocare Tanzania is a joint venture between Thyrocare India and the Kastipharm Group, operating in the diagnostic and healthcare services sector. The capital infusion aims to strengthen operational capabilities and meet working capital requirements.

Financial and Operational Snapshot

For the year ended December 31, 2025, Thyrocare Tanzania reported a turnover of ₹1.84 crore and a net worth of ₹(0.32) crore. The company has an authorised capital of 10,00,000 ordinary shares with a face value of 10,000 Tanzanian Shillings each.

The Board of Thyrocare Technologies has approved a total investment of up to ₹15 crore in one or more tranches, depending on business needs. With the latest infusion, the total investment made so far stands at USD 11,50,020 (approximately ₹10.01 crore).

Transaction Structure and Shareholding

The investment qualifies as a related party transaction, as Thyrocare Tanzania is a subsidiary. However, the company clarified that the transaction has been carried out at arm’s length, and promoters do not have any additional interest beyond the disclosed arrangement.

Post allotment, Thyrocare continues to hold 57.25% equity shares in the subsidiary, while maintaining 100% holding in CCPS. The consideration for the investment has been made entirely in cash.

Thyrocare Share Price Performance

On February 25, 2026, Thyrocare share price opened at ₹405.95, touching the day’s high at ₹405.95, as of 11:20 AM on the NSE.

Also Read: Best Long-Term Stocks in Feb 2026 – 5yr CAGR Basis!

Conclusion

The fresh capital infusion reflects Thyrocare’s commitment to strengthening its international presence and expanding diagnostic services in Africa. As healthcare demand grows in emerging markets, strategic investments like this could enhance long-term growth prospects. Further tranches may follow based on operational requirements, underscoring the company’s phased expansion strategy.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.